Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
Related Questions
Is there additional concern for late cardiac toxicity when using ultrahypofractionated breast radiation protocols, given that the BED to the heart is higher?
What are your top takeaways in Medical Oncology from SABCS 2025?
Is it appropriate to use bolus with hypofractionated PMRT?
Would you forgo lumpectomy cavity boost for grade 1 papillary carcinoma with associated grade 1 DCIS that has been resected with good margins?
Would you offer ultrahypofractionated 5-fraction whole breast only for a women with ER-/HER2+/cN+ disease with pCR following neoadjuvant systemic therapy?
Would you consider RNI alone without CW for an isolated nodal recurrence after treatment with mastectomy and SNB for an early-stage breast cancer with no prior RT?
Given the 10-year outcomes of UK FAST-Forward presented at ESTRO, how have you expanded the use of ultra-hypofractionation in your practice?
Have the 10-year results from UK FAST-Forward presented at ESTRO 2025 impacted your practice with regard to patient selection?
Would a longstanding diagnosis of multiple sclerosis impact your radiation recommendations for a patient with breast cancer?
How would you manage an elderly patient with a de novo TNBC in the setting of a remote prior ipsilateral breast cancer s/p mastectomy and implant?
